Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Routine IM Influenza Immunization and Administration by Jet-injector (Med-Jet H4™) in Healthy Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female adults~* 18 to 49 years of age~* body mass index (BMI) of ≥ 18 kg/m2 and ≤ 32 kg/m2~* Must be accessible by phone on a consistent basis and be available for the D21 blood draw~Exclusion Criteria:~* Any influenza vaccine during the 2016-2017 season~* significant acute or chronic, uncontrolled medical or neuropsychiatric illness~* confirmed or suspected immunosuppressive condition or immunodeficiency~* history of autoimmune disease, cancer, or treatment for cancer within 3 years of study vaccine administration~* Receipt of any investigational or non-registered product within 30 days prior to study enrolment~* receipt of systemic glucocorticoids at a dose exceeding 10 mg of prednisone per day, or equivalent, for more than 7 consecutive days or for 10 or more days in total within 1 month of vaccine administration~* any other cytotoxic or immunosuppressant drug or any globulin preparation within 3 months of vaccination~* blood transfusion within 90 days of study vaccination~* Although there is no known danger from influenza vaccination during pregnancy, pregnant women will be excluded since the efficacy of the Med-Jet delivery system is not yet known~* known drug or alcohol abuse will also be excluded.~Temporary Contraindications Following the resolution, in the opinion of the Investigator, of the following temporary conditions that constitute contraindications to administration of study vaccine, subjects may be enrolled in the study:~* Temperature ≥ 38.0 ºC within 24 hours prior to randomization.~* Acute cold symptoms such as upper respiratory tract infection symptoms, with or without fever, which typically resolve in 48 to 72 hours prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Jet injector (Type: ACTIVE_COMPARATOR): 40 participants will receive Fluviral influenza vaccine using the Med-Jet H4
- IM injection (pre-filled syringe) (Type: ACTIVE_COMPARATOR): 20 participants will receive Fluviral influenza vaccine using pre-filled syringes for time-motion comparison to Med-Jet H4
- IM injection (multi-dose vial) (Type: ACTIVE_COMPARATOR): 20 participants will receive Fluviral influenza vaccine using a multi-dose vial for time-motion comparison to Med-Jet H4

Based on this trial design, predict the completion outcome and termination type (if applicable).